Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829636 | 0.75 | CYP3A4 (0.44) | ALDH1A1CYP2C19CYP2C9CYP3A4TDP1 | |
| SCHEMBL17063254 | 0.72 | AMPD2 (0.44) | ALDH1A1CYP3A4TDP1LMNAFKBP1A | |
| SCHEMBL20051948 | 0.70 | ELANE (0.57) | ALDH1A1TDP1LMNAKMT2AELANE | |
| SCHEMBL4748917 | 0.69 | AMPD2 (0.44) | ALDH1A1CYP3A4LMNAMAPTAMPD2 | |
| SCHEMBL6738188 | 0.69 | ALDH1A1 (0.46) | ALDH1A1TDP1LMNAFKBP1AMAPT | |
| SCHEMBL11492920 | 0.69 | FKBP1A (0.48) | ALDH1A1CYP2C19CYP2C9TDP1FKBP1A | |
| SCHEMBL9031247 | 0.68 | ALDH1A1 (0.53) | ALDH1A1TDP1FKBP1AKMT2ASMN1; SMN2 | |
| SCHEMBL6049147 | 0.68 | ALDH1A1 (0.53) | ALDH1A1TDP1FKBP1AKMT2ASMN1; SMN2 | |
| SCHEMBL1012463 | 0.68 | FKBP1A (0.45) | ALDH1A1CYP2C19CYP2C9TDP1FKBP1A | |
| SCHEMBL22004724 | 0.68 | FKBP1A (0.47) | ALDH1A1CYP2C19CYP2C9FKBP1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| CN-101917981-B | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2012-11-14 | — | — | CN | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101917981-A | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-12-15 | — | — | CN | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | ALDH1A1 985/4885CYP2C19 2452/4885CYP2C9 3447/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | ALDH1A1 1567/4885CYP2C19 2108/4885CYP2C9 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.